ES2194513T3 - Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas. - Google Patents
Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas.Info
- Publication number
- ES2194513T3 ES2194513T3 ES99948982T ES99948982T ES2194513T3 ES 2194513 T3 ES2194513 T3 ES 2194513T3 ES 99948982 T ES99948982 T ES 99948982T ES 99948982 T ES99948982 T ES 99948982T ES 2194513 T3 ES2194513 T3 ES 2194513T3
- Authority
- ES
- Spain
- Prior art keywords
- acid
- component
- patopsychological
- neurological
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- ZHKQAQKGVKBJPP-YUZLPWPTSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2NC1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZHKQAQKGVKBJPP-YUZLPWPTSA-N 0.000 abstract 1
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 abstract 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 1
- AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 abstract 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 abstract 1
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 abstract 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 abstract 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000008106 phosphatidylserines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Composición que comprende ingredientes activos y, opcionalmente, una o más substancias nutricionales, excipientes o auxiliares sólidos, líquidos y/o semilíquidos, caracterizada porque los ingredientes activos constan de a) un componente A que consta de una o más fosfatidil serinas, b) un componente B que consta de uno o más compuestos seleccionados entre ácido de dihidrofólico, ácido tetrahidrofólico, ácido 5-metiltetrahidrofólico, ácido 5-formiltetrahidrofólico, ácido 10-formiltetrahidrofólico, ácido 5, 10-metilenotetrahidrofólico, ácido 5, 10-meteniltetrahidrofólico o sus sales fisiológicamente aceptables c) un componente C que consta de uno o más compuestos seleccionados entre donadores de metilo y metileno, con la condición de que las fosfatidil serina y los compuestos del componente B no formen parte del componente C.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10623098P | 1998-10-30 | 1998-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2194513T3 true ES2194513T3 (es) | 2003-11-16 |
Family
ID=22310256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99948982T Expired - Lifetime ES2194513T3 (es) | 1998-10-30 | 1999-10-13 | Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas. |
Country Status (9)
Country | Link |
---|---|
US (1) | US6514973B1 (es) |
EP (1) | EP1124559B1 (es) |
JP (1) | JP2002528507A (es) |
AT (1) | ATE235244T1 (es) |
AU (1) | AU6202299A (es) |
CA (1) | CA2348390C (es) |
DE (1) | DE69906345T2 (es) |
ES (1) | ES2194513T3 (es) |
WO (1) | WO2000025793A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7591995B2 (en) | 1999-10-15 | 2009-09-22 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
US20020176881A1 (en) * | 2001-01-26 | 2002-11-28 | George Verlaan | Rehydration composition |
JP2004520845A (ja) * | 2001-03-26 | 2004-07-15 | ギヴエンテイス・ゲゼルシヤフト・ミット・ベシュレンクテル・ハフツング | 認知能力を高めるための食品 |
EP1302196A1 (de) * | 2001-10-16 | 2003-04-16 | Habinger, René, Ing. Mag. | Intelligenzfördernde Zahncreme |
PL375076A1 (en) * | 2002-06-19 | 2005-11-14 | N.V.Nutricia | Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
US7033612B2 (en) * | 2003-01-03 | 2006-04-25 | Kang David S | Composition and method for treating age-related disorders |
IL154318A (en) | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
IL158139A0 (en) * | 2003-09-25 | 2004-09-27 | Enzymotec Ltd | Stabilized formulations of phosphatidyl serine |
US7935365B2 (en) * | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
US20050130937A1 (en) * | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
US8052992B2 (en) * | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
EP1645276A1 (en) * | 2004-10-08 | 2006-04-12 | Wageningen Centre for Food Sciences | Treatment of neurodegenerative disorders |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
CA2587406A1 (en) * | 2004-11-16 | 2006-05-26 | Limerick Neurosciences, Inc. | Methods and compositions for treating pain |
CN101983057A (zh) | 2008-01-30 | 2011-03-02 | 新加坡科技研究局 | 用咪唑和咪唑啉化合物治疗纤维变性和癌症的方法 |
WO2009123569A1 (en) * | 2008-03-31 | 2009-10-08 | Agency For Science, Technology And Research | Method for treating neurological disorders with imidazolium and imidazolinium compounds |
US8546104B2 (en) * | 2008-08-07 | 2013-10-01 | Lipogen Ltd. | Processes for the preparation of phosphatide salts |
EP3949973A3 (en) | 2010-02-12 | 2022-07-06 | Gentelon, Inc. | Compositions and methods for treating depression |
WO2014018873A2 (en) * | 2012-07-27 | 2014-01-30 | Chemic Laboratories Inc. | Compositions comprising folic acid derivatives. their preparations and methods of use |
US11110113B2 (en) | 2016-11-03 | 2021-09-07 | Gentelon, Inc. | Compositions and methods for treating depression |
CN113164440A (zh) | 2018-11-30 | 2021-07-23 | 贝斯以色列女执事医疗中心有限公司 | 减少癌症患者的主要血栓事件的组合物和方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MC2041A1 (fr) * | 1988-06-24 | 1990-05-30 | Johannes Cornelius Str Andries | Agents anti-atherogenic |
IT1229517B (it) * | 1989-01-31 | 1991-09-03 | Bioresearch Spa | Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. |
IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
DE4117629A1 (de) * | 1991-05-29 | 1992-12-03 | Max Planck Gesellschaft | Phospatidylserine |
PT877563E (pt) * | 1996-01-31 | 2004-08-31 | Univ South Alabama | Preparacoes alimentares e vitaminicas contendo o isomero natural de folatos reduzidos |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
WO1999037155A1 (en) | 1998-01-27 | 1999-07-29 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
-
1999
- 1999-10-13 US US09/830,352 patent/US6514973B1/en not_active Expired - Fee Related
- 1999-10-13 ES ES99948982T patent/ES2194513T3/es not_active Expired - Lifetime
- 1999-10-13 JP JP2000579233A patent/JP2002528507A/ja active Pending
- 1999-10-13 CA CA002348390A patent/CA2348390C/en not_active Expired - Fee Related
- 1999-10-13 WO PCT/EP1999/007688 patent/WO2000025793A1/en active IP Right Grant
- 1999-10-13 AT AT99948982T patent/ATE235244T1/de not_active IP Right Cessation
- 1999-10-13 AU AU62022/99A patent/AU6202299A/en not_active Abandoned
- 1999-10-13 DE DE69906345T patent/DE69906345T2/de not_active Expired - Lifetime
- 1999-10-13 EP EP99948982A patent/EP1124559B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69906345T2 (de) | 2004-02-12 |
US6514973B1 (en) | 2003-02-04 |
JP2002528507A (ja) | 2002-09-03 |
AU6202299A (en) | 2000-05-22 |
EP1124559B1 (en) | 2003-03-26 |
DE69906345D1 (de) | 2003-04-30 |
EP1124559A1 (en) | 2001-08-22 |
ATE235244T1 (de) | 2003-04-15 |
CA2348390C (en) | 2008-11-25 |
CA2348390A1 (en) | 2000-05-11 |
WO2000025793A1 (en) | 2000-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2194513T3 (es) | Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas. | |
AR010348A1 (es) | Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen | |
AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
ES2058185T3 (es) | Derivados de camptotecina y procedimiento para su preparacion. | |
DK0960107T3 (da) | 6-Thiosubstituerede paclitaxeler | |
ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
ECSP066763A (es) | Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes | |
DE3851776D1 (de) | Verwendung von IGF-II zur Behandlung von Knochenkrankheiten. | |
AR029941A1 (es) | Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen | |
PT971717E (pt) | Amino-acucar citotoxico e derivados de acucar afins de indolopirrolocarbazois | |
CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
PA8457001A1 (es) | Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol | |
AR035284A1 (es) | Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion | |
DE69803773D1 (de) | Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion | |
ES2052484T1 (es) | N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
AR021463A1 (es) | Antibiotico de piridona con perfil de seguridad mejorado | |
IT1284873B1 (it) | Derivati stabili di ubichinolo procedimenti per la loro produzione e loro impiego farmaceutico | |
SE8403659D0 (sv) | Synergistic pharmaceutical composition | |
ES2132283T3 (es) | Derivados n-heteroaril sustituidos de propanamida utiles en el tratamiento de enfermedades cardiovasculares. | |
AR023644A1 (es) | 3-aril-pirazoles substituidos, procedimiento para su obtencion, procedimiento para la lucha contra plantas indeseables, empleo de los mismos contra plantasindeseables y/o como fungicida, y composicion para el tratamiento de plantas | |
ES2129392T3 (es) | Derivados de di-lisogangliosidos. |